Posts by Mourabit Halima

The 2025 Annual Meeting of the American Society of Hematology (ASH 2025) recently concluded successfully in Orlando, USA. As the most influential annual event in hematology, this year’s meeting showcased multiple breakthrough advances in lymphoma, offering new directions for optimizing clinical practice.

The combination of antibody–drug conjugates (ADCs) and immune checkpoint inhibitors (ICIs) is rapidly transforming the clinical management of urothelial carcinoma. Meanwhile, circulating tumor DNA (ctDNA) is emerging as a highly promising biomarker, offering critical support for precision medicine and bladder-preserving treatment strategies.

The Infectious Diseases Society of America (IDSA) has recently released its Clinical Practice Guidelines for the Treatment and Management of Complicated Urinary Tract Infections (cUTI)—the first IDSA guideline dedicated specifically to cUTI. The updated guideline revises the definition of cUTI and proposes a four-step framework to support individualized empiric treatment decisions.

Recently, the Department of Urology at Jiangsu Provincial People’s Hospital, led by Professor Qiang Lü, published a multicenter study in EClinicalMedicine (CAS Zone 1, Impact Factor = 10.0). By integrating multicenter MRI data, the research team developed a multimodal fusion–based deep learning model designed to achieve noninvasive preoperative survival prediction in bladder cancer patients.

Recently, the 15th Shanghai Urologic Oncology Academic Conference—hosted by the Shanghai Anti-Cancer Association under the theme “Precision Integration · Intelligent Leadership”—brought together leading scholars from around the world to explore advances in urologic oncology.

Radical prostatectomy (RP) remains the primary surgical treatment for localized prostate cancer. However, a substantial proportion of patients experience biochemical recurrence (BCR) following surgery, which is closely associated with disease progression and prostate cancer–specific mortality. Consequently, reducing postoperative BCR and improving long-term outcomes in prostate cancer patients have become major areas of clinical research focus.

A multidisciplinary team led by Professors Xuesong Li and Qi  Tangfrom the Institute of Urology and Department of Urology, Peking University First Hospital, in collaboration with Professor  Jianhua  Zhang’s team from the Department of Nuclear Medicine and Professor  Xiaoying Li’s team from the Department of Radiation Oncology, has published an original research article in Clinical Nuclear Medicine (Impact Factor: 9.6), the official journal of the Society of Nuclear Medicine and Molecular Imaging.

In 2025, the 15th Shanghai Urologic Oncology Academic Conference was grandly held in Pudong, Shanghai. The meeting brought together leading experts in urologic oncology from China and around the world to engage in in-depth discussions on advances in the diagnosis and treatment of urothelial carcinoma, prostate cancer, renal cell carcinoma, and other major genitourinary malignancies.